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ABSTRACT 
Radiation therapy is widely used in the management of intracranial (including sellar and 
parasellar) and systemic disorders. Whilst in a number of cases the irradiation aims to prevent 
the growth or re-growth and to control the hormonal hypersecretion of a pituitary tumor, in a 
number of others, it adversely affects the hypothalamo-pituitary function simply because this 
area receives significant doses of radiation delivered for non-hypothalamo-pituitary disorders. 
Pituitary irradiation is usually offered post-operatively for tumors of the sellar and parasellar 
area and its efficacy varies widely mainly depending on the type of tumor, degree of 
hormonal hypersecretion and radiation technique and schedule used. The main long-term 
complications include hypopituitarism, optic neuropathy, cerebrovascular morbidity and 
second brain tumors. Radiation technique and schedule are important determinants of these 
adverse effects.  
KEY POINTS 
 Radiation therapy is widely used in the management of intracranial (including sellar and 
parasellar) and systemic disorders. 
 Its place in the management algorithm of pituitary tumors depends on the type of tumor 
and is usually recommended post-operatively to prevent relapse or to control hormonal 
hypersecretion. 
 Its efficacy varies widely mainly depending on the type of tumor, degree of hormonal 
hypersecretion and radiation technique and schedule used. 
 With the advances in radiation planning and delivery, the long-term complications have 
improved, although hypopituitarism remains the protagonist in the list of adverse 
sequelae. 
A. INTRODUCTION 
Radiation therapy is widely used in the management of intracranial (including sellar and 
parasellar) and systemic disorders. These mainly include pituitary adenomas, other 
(para)sellar tumors (eg. craniopharyngiomas, meningiomas, germinomas, schwannomas, 
chordomas/chordosarcomas, haemangiopericytomas, gliomas, pituicytomas, pinealomas, 
medulloblastomas, brain metastases, vascular malformations), hematological malignancies 
(eg. acute lymphoblastic leukemia, lymphomas), face, neck and skull base tumors (eg. 
nasopharyngeal carcinomas) (1). Whilst in a number of cases the irradiation aims to prevent 
the growth or re-growth and to control the hormonal hypersecretion of a pituitary tumor, in a 
number of others, it adversely affects the hypothalamo-pituitary function simply because this 
area receives significant doses of radiation offered for non-hypothalamo-pituitary disorders. 
This review will focus on the efficacy of various types of radiation techniques in the most 
common pituitary tumors and on the complications following irradiation which has included 
the hypothalamo-pituitary area. 
 
B. EFFICACY OF PITUITARY IRRADIATION  
The aim of radiation treatments to the sellar region is to prevent tumour (re)growth and to 
control the hormonal hypersection, while sparing the surrounding normal structures. 
Conventional fractionated radiotherapy delivers megavoltage doses of irradiation in fractions 
separated over time. The irradiation is given through multiple beams from a high energy 
radiation source focused on the tumor. Radiation treatments are most commonly delivered 
through photons (high energy X-rays) generated by a linear accelerator (LINAC). Cobalt 60 
as a source of high energy gamma radiation has been mostly replaced with the exception of a 
multiheaded cobalt unit (gamma knife). Charged particle beams in the form of photons and 
more recently helium and carbon ions have been also used as therapeutic radiation sources. 
Localised irradiation is achieved by offering treatment in 3-4 beams each shaped to conform 
to the shape of the tumor by using a multileaf collimator (MLC). MLC leaves can also 
modulate the intensity of radiation [intensity modulated radiotherapy (IMRT)] (1). In 
pituitary adenomas, the most commonly used protocol includes a total dose of 45-50 Gy 
offered in fractions of 1.6-1.8 Gy, 4-5 times per week during 5-6 weeks. Stereotactic 
techniques are related with further improvement in immobilization using relocatable or fixed 
frames, improved imaging and more precise treatment delivery. Stereotactic irradiation is 
offered as single fraction radiotherapy using either cobalt 60 gamma radiation emitting 
sources (gamma knife) or a LINAC or as stereotactic conformal radiotherapy delivered as 
fractionated treatment using a LINAC.  
1. Acromegaly 
The aims of the treatment of acromegaly are to inhibit GH hypersecretion, normalise IGF-I 
levels and reduce or control tumor growth, leading to symptom control and minimizing the 
associated clinical signs and co-morbidities (2). Biochemical control is generally defined as a 
normal IGF-I for age and gender and a GH less than 1.0 ng/ml on an oral glucose tolerance 
test. With sensitive assays, a GH of less than 0.4 ng/ml would be consistent with remission 
(2). Radiotherapy is generally reserved as third or second-line treatment in cases in which 
surgery and/or medical therapy have not achieved tumor growth control or normalization of 
hormone levels. It may also be used for those controlled on medical therapy aiming to stop it 
after the irradiation has led to hormonal control (2). Based on series with strict remission 
criteria, fractionated radiotherapy achieves remission rates in 50-60% of the patients within 
10 years (Table 1). Predictive factors for remission are the initial GH and IGF-I levels (3,4). 
It has been shown that within the first 2 years after irradiation, the GH levels decrease by 50-
70% followed by a slow gradual reduction over the next 10-20 years (5). Data on the efficacy 
of fractionated proton beam irradiation in acromegaly are limited with no conclusive 
evidence on the superiority of this treatment. Stereotactic radiosurgery has been used in 
patients with small residual tumor, not close to the optic pathways and biochemical remission 
has been reported in 35-100%; the variable rates reflect the different observation periods and 
the different criteria used to assess control of the disease (6). 
2. Cushing’s disease 
Radiotherapy is almost exclusively used as a second rather than as a primary choice therapy 
in corticotroph adenomas following non-curative surgery (in these cases medical treatment is 
usually offered until irradiation provides the desired results). The most widely accepted 
criterion to define remission after irradiation is normalization of the 24-hour urinary free 
cortisol but additional criteria [as normal basal ACTH and/or cortisol levels and suppression 
of cortisol on low-dose dexamethasone test) are variably used. The remission rates of 
hypercortisolism range from 42 to 83% without clear difference between the types of 
radiotherapy used (Table 2). Patients with Cushing’s disease seem to have a shorter latency 
before achieving remission compared with those with acromegaly. Corticotroph tumor 
control is reported in 93-100% of the cases (7).  
 
3. Prolactinomas 
Radiotherapy is reserved for patients with prolactinoma not responding to dopamine agonists 
or surgery or in the rare cases of malignant adenoma (8). It aims to control tumor growth and 
to achieve normoprolactinemia. The hormonal response rates vary widely (0-100%) (8).  
 
4. Non-Functioning pituitary adenomas (NFA) 
Currently, radiotherapy is offered post-operatively to patients with NFA less frequently than 
previously, mainly due to the long-term risk of hypopituitarism and its indications are still not 
absolutely evident (9). However, it is generally accepted that radiotherapy is not required in 
patients with no residual tumor as the risk of relapse is very low (10). Based on a number of 
series, the 5-years regrowth rate following post-operative irradiation ranges between 0-28% 
(11,12,13). Randomised studies comparing surgery with or without radiotherapy are lacking; 
however, a report comparing the results of two institutions in the UK with different treatment 
strategies clearly showed the benefit of radiotherapy on tumor recurrence (14). Gamma knife 
radiosurgery offers tumor stabilization in 60-78% during mean/median follow-up periods 45-
78 months with rates of tumor recurrence between 3-7% (15). 
5. Craniopharyngiomas 
Until 1937, when Carpenter et al. (16) first described the beneficial effects of radiotherapy 
following aspiration of cyst contents in 4 cases, craniopharyngiomas were considered 
radioresistant (17). The benefit of radiotherapy in preventing tumor recurrence has been 
demonstrated in a number of reports. Series with radiological confirmation of the radicality of 
resection show that the recurrence rates following gross total removal range between 0-62% 
at 10 years follow-up. These are significantly lower than those reported after partial or 
subtotal resection (25-100% at 10 years follow-up). In cases of limited surgery, adjuvant 
radiotherapy improves significantly the local control rates (recurrence rates 10-63% at 10 
years follow-up) (18,17).  Finally, radiotherapy alone provides 10 years recurrence rates 
ranging between 0-23% (17). These results were based on conventional fractionated external 
beam radiotherapy and tumour control rates with newer higher precision techniques, such as 
fractionated stereotactic conformal radiotherapy have remained optimal with 5 years 
progression free survival more than 90% (19). The beneficial effect of radiotherapy (preceded 
or not by second surgery) in recurrent lesions has been clearly shown (18). Stereotactic 
radiosurgery achieves tumor control in a substantial number of patients with small volume 
lesions and reported 5 years progression free survival ranges between 61-68% (19). It may be 
particularly useful for well-defined residual disease following surgery or for the treatment of 
small solid recurrent tumors, particularly after failure of conventional radiotherapy.  
 
C. COMPLICATIONS OF PITUITARY IRRADIATION 
These are shown in Tables 3 and 4 with the most common being radiation-induced 
hypopituitarism. 
 
D. FUTURE CONSIDERATIONS 
Irradiation remains an important tool in our therapeutic armamentarium for intracranial 
(including sellar and parasellar) and systemic disorders. Studies comparing the efficacy and 
safety of different radiation techniques - particularly for sellar and parasellar lesions - are 
required aiming to provide reliable data on the place of each technique in the management 
algorithm. Furthermore, prospective studies of consecutive, non-selected patients relying on 
robust diagnostic criteria and on the biological effective dose to the hypothalamus-pituitary 
are needed aiming to clarify timing and frequency of damage to each axis and to provide the 
basis for safe and cost-effective surveillance protocols.  
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Table 1. Series with outcome of fractionated radiotherapy in patients with acromegaly. 
Reference Type of 
Radiotherapy 
No of 
patients 
Follow-up Remission criteria Remission rate 
(20) Conventional 46 Mean 7.6 years GH < 2.5 ng/ml 21% 
(3) Conventional 128 Mean 11.5 years GH < 2.5 mcg/l 53% at 10 years 
(21) 
 
Conventional 67 Mean 10 years GH < 2.5 mcg/l 
IGF-I normal 
58% 
55% 
      (4) 
 
Conventional 656 Median 7 years GH < 2.5 ng/ml 
IGF-I normal 
60% at 10 years 
63% at 10 years 
(22) Fractionated stereotactic 18 Median 39 months GH < 2.5 ng/ml 
or 
GH < 1 ng/ml  on oral 
glucose tolerance test and 
IGF-I normal 
50% at 5 years 
 
 
Table 2. Series with outcome of radiotherapy in patients with Cushing’s disease. 
Reference Type of 
radiotherapy 
No of 
patients 
Follow-up Remission criteria Remission 
rate 
      (23) 
 
Conventional 86 Mean 18 years Clinical remission / normal excretion of urinary steroids / serum 
cortisol < 80nmol/l on low dose dexamethasone suppression test 
 
64% 
(24) 
 
 
Gamma knife 18 Mean 17 years Clinical remission / normal or low serum 
cortisol and plasma ACTH / normal or subnormal urinary free 
cortisol / normal response on dexamethasone suppression test 
 
83% 
(25) 
 
Gamma knife 
 
 
 
40 
 
Mean 5 years 
 
 
 
Normal urinary free cortisol  / normal response on low dose 
dexamethasone suppression test 
 
42% 
 
 (26) 
 
Gamma knife 
 
 
90 Mean 4 years Normal urinary free cortisol 54% 
      (27) 
 
Conventional 40 Mean 9 years Normal urinary free cortisol /serum cortisol / normal response 
on overnight dexamethasone suppression test 
 
78% 
(28) Proton 
stereotactic 
33 Mean 5 years Normal urinary free cortisol 52% 
Table 3. Complications of pituitary irradiation (1, 29-41).  
COMPLICATIONS TYPE COMMENTS 
Short-term 
 
Temporary skin changes (erythema) 
Hair loss 
Tiredness 
Nausea 
Headache 
Hearing problems 
Resolve spontaneously within days to weeks after the completion of 
therapy. 
Long-term Radiation-induced hypopituitarism Attributed to degenerative changes in glial cells leading to lack of 
trophic neural support, demyelination and hypothalamic damage, as 
well as to vascular derangements leading to endothelial cell death, 
obliteration of small vessels and tissue necrosis. 
 
Onset and severity affected by total radiation dose, dose fractionation 
(fraction size and time between fractions for tissue repair), length of 
follow-up (as late as 15-20 years after irradiation) and previous 
damage to the hypothalamo-pituitary system (eg. compression by 
tumor or surgery). 
 
There is differential radiosensitivity with GH and gonadotroph axes 
been affected first, followed by ACTH and TSH axes damage (also 
central precocious puberty may occur with doses 18-24 Gy). 
 
Frequencies for each axis and dose regimes are shown in Table 4. 
 
Predictors of pituitary dysfunction following gamma knife 
radiosurgery include mean dose to stalk/pituitary (cut-offs 15.7 and 
7.3 Gy, respectively) - during median follow-up of 63 months, new 
hormone deficits reported in 29% of patients after 7.6-13.2 Gy, in 
39% after 13.3-19.1 Gy and in 83% after > 19.1 Gy. 
 
Annual long-term surveillance of the pituitary function is required. 
 
Radiation-induced hyperprolactinemia 
 
Attributed to hypothalamic damage and reduction of dopamine. 
 
Mainly following total dose > 30 Gy. 
 
20-50% in adults – less common in children. 
 
Gradual decline may occur with time suggesting direct radiation-
induced damage to lactotroph cells. 
 
Cranial neuropathy Multiple cranial nerves, including II, III, IV, V, and VI, are at risk 
with reported rates 1.3-0.6% following various types of radiotherapy. 
 
Radiation-induced optic neuropathy Typically presents with sudden, painless, unilateral visual loss, 
although bilateral involvement may rapidly follow. Visual acuity 
decreases to a variable degree and visual fields may show any pattern 
of optic nerve or chiasmal defects. No effective treatment. 
Attributed to microvascular obliteration in optic pathways. 
Onset ranges between 3 months to > 8 years after radiation exposure. 
Conventional radiotherapy may cause optic neuropathy resulting in 
visual deficit in 1–3% and radiosurgery in 2–5% of the patients. 
Susceptibility increases with increasing age, co-morbid diabetes, pre-
existing compression to the optic nerves and chiasm, volume of the 
optic apparatus exposed to high-dose irradiation (for gamma knife) 
and prior external beam radiation therapy. 
Frequency is dose-dependent, increasing with total doses > 50-55 Gy 
(fractionated radiotherapy) or single doses > 10 Gy (stereotactic 
radiosurgery) or radiation fraction size > 2 Gy (fractionated 
radiotherapy) or total dose to the optic pathway > 8 Gy. For tumors 
close to the chiasm, even total doses of 45 Gy may cause optic 
neuropathy and the distance between tumor margin and optic 
apparatus should be at least 3 mm. 
Radiation-induced brain necrosis 
 
May occur in the treated peri-tumoral area or distal from the original 
tumor but always within the radiation fields. The patients may 
present with raised intracranial pressure due to edema, cognitive 
dysfunction, seizures or focal neurological signs related to the 
position of the lesion. 
Related with microvascular obliteration, ischemic necrosis and 
demyelination of white matter. 
Onset ranges between a few months to > 40 years after the 
irradiation. 
The risk increases with increasing total dose and fraction size and it 
is almost unknown with total doses 45-50 Gy in fractions of < 2 Gy. 
Cerebrovascular accidents 
 
Cerebrovascular mortality has been found increased in patients with 
pituitary adenoma treated by radiotherapy compared with the general 
population. 
Related to atherogenesis to the vascular lining from the radiotoxicity  
Risk factors include older age, previous aggressive intracranial 
surgery and total dose > 45 Gy. 
Particularly in patients with acromegaly, radiotherapy has been 
associated with increased mortality with cerebrovascular disease 
being the main cause of death.  
Second brain tumor In a series of patients irradiated for pituitary adenoma probability 2% 
at 20 years, but another series comparing patients with pituitary 
adenoma and treated by surgery alone or postoperative radiotherapy 
did not confirm increased risk. 
Most commonly meningiomas, gliomas, chondrosarcomas. 
Risk factors including radiation thresholds not defined. 
Cognitive dysfunction No consistent data and in studies using extensive psychometric 
testing the effect of irradiation could not be clearly distinguished 
from that of other interventions or of the tumor itself. 
Quality of life Patients with non-functioning pituitary adenoma treated by 
rariotherapy show compromised scores in the areas of energy levels 
and perception of the overall health in health-related quality of life 
questionnaires. 
 
Table 4. Hypopituitarism after cranial radiotherapy (1,33,42,43).  
Condition treated with radiotherapy Radiation details Pituitary hormone deficits 
Leukemia and lymphoma Fractionated total body irradiation  
(7-16 Gy) 
Isolated GH deficiency in children 
Leukemia and lymphoma Fractionated prophylactic cranial irradiation  
(18-24 Gy) 
GH deficiency in children 
Small risk of other deficits in children/adults 
Non-pituitary brain tumors Conventional fractionated cranial irradiation 
(30-50 Gy) 
GH deficiency 30-100% (higher in children) 
FSH/LH deficiency ~30% 
ACTH deficiency ~20-30% 
TSH deficiency ~10% 
Nasopharyngeal carcinoma and skull-base 
tumours 
Conventional fractionated cranial irradiation 
(50-70 Gy) 
GH deficiency 55-100% 
FSH/LH deficiency ~35-82% 
ACTH deficiency ~18-25% 
TSH deficiency ~15-45% 
Pituitary tumors Conventional fractionated cranial irradiation 
(30-50 Gy) 
GH deficiency ~100% 
FSH/LH deficiency ~65% 
ACTH deficiency ~40-50% 
TSH deficiency ~50% 
Limitations of the studies these data rely on include selection bias of patients (eg. only the symptomatic ones may have been tested), various 
sample sizes, different diagnostic tests and criteria, various radiotherapy schedules (biological effective dose not usually estimated), variable 
follow-up, impact of previous cranial surgery or chemotherapy. 
 
